Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jul;53(7):E21-E23.
doi: 10.1002/ppul.24043. Epub 2018 May 23.

Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis

T Spencer Poore  1 , Isabel Virella-Lowell  1   2   3 , Jennifer S Guimbellot  1   2   3
Affiliations
Case Reports

Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis

T Spencer Poore et al. Pediatr Pulmonol. 2018 Jul.

Abstract

Presentation: Patient is a 6-year-old male with CF, MRSA colonization, and pancreatic insufficiency that presented with worsening ppFEV1 and systemic symptoms despite multiple interventions. BAL grew NTM, Stenotrophomonas maltophilia, and Inquilinus limosus, a rare organism found in patients with CF.

Course: I. limosus treatment was deferred. Despite treatment of other pathogens, symptoms worsened. I. limosus was targeted with meropenem, amikacin, and ciprofloxacin along with clindamycin for MRSA colonization. Within weeks, symptoms had resolved with ppFEV1 improvement.

Discussion: This case discusses the importance of a rare organism in the CF population. Targeting I. limosus was key to recovery, revealing its potential pathogenicity.

Keywords: Inquilinus limosus; MRSA; cystic fibrosis; infections; nontuberculous mycobacterium.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Timeline of patient's clinical course over a 6 month period surrounding I. limosus isolation. Box values are ppFEV1. Circled values on timeline are months from index presentation
See this image and copyright information in PMC

References

    1. Chiron R, Marchandin H, Counil F, et al. Clinical and microbiological features of Inquilinus sp. isolates from five patients with cystic fibrosis. J Clin Microbiol. 2005; 43:3938–3943. - PMC - PubMed
    1. Cicatiello AG, Iula DV, Pagliuca C, et al. Identification of Inquilinus limosus in cystic fibrosis: a first report in Italy. New Microbiol. 2014; 37:567–571. - PubMed
    1. McHugh KE, Rhoads DD, Wilson DA, Highland KB, Richter SS, Procop GW. Inquilinus limosus in pulmonary disease: case report and review of the literature. Diagn Microbiol Infect Dis. 2016; 86:446–449. - PubMed
    1. Schmoldt S, Latzin P, Heesemann J, Griese M, Imhof A, Hogardt M. Clonal analysis of Inquilinus limosus isolates from six cystic fibrosis patients and specific serum antibody response. J Med Microbiol. 2006; 55:1425–1433. - PubMed
    1. Jung HM, Lee JS, Bae HM, et al. Inquilinus ginsengisoli sp. nov., isolated from soil of a ginseng field. Int J Syst Evol Microbiol. 2011; 61:201–204. - PubMed

Publication types

MeSH terms